Highlights from ESMO Asia 2024 by Angela Lamarca
The ESMO Asia Congress 2024 is currently taking place from December 6 to 8, 2024, in Singapore. This annual congress focuses on multidisciplinary oncology in the Asian region, providing a platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field.
Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared some insights from the conference as follows:
“Great session today at ESMOAsia24
A pleasure to co-chair with SuPunChoo. Thanks to the authors and discussants for a great job and fantastic discussions.”
“Update form CHECKMATE-9DW trial in HCC – Asian population with IpiNivo
94% with lenva in control arm Similar benefit despite higher VHB (62%) – aetiology of no much relevance (again).
Less use of high dose steroids (vs general population).”
Higher rate of HER-2 2+ included (28% vs 13% in general population).
Similar ORR 42%.
Safety.”
Durvalumab being tested with nonCisGem chemotherapy, PS2 or ampullary.
Early results from first 62 pts (non-european) treated with 1hour infusion in cycle 1 and 30 min in cycle =>2. 30 min infusion is safe.”
By the way beautiful discussion by Lorenza Rimassa. Here the behind the scenes.
“We do travel a lot on our own, but we are never really alone
Great to see you Matteo Lambertini, as usual at ESMOAsia24 ESMOLGP.”
“Revisiting Malignant Ascitis in The European Society for Medical Oncology (ESMO) ESMOAsia24
Intraperitoneal M701 (anti-EpCAM x anti-CD3 bispecific antibody)+systemic therapy.
Puncture-free survival as end-point.”
“So coming back to TP53 Y220C mutation Topic discussed at ESMOAsia24
Targetable alteration. Present on 8% of #PDAC (94% with KRAS co-mutated).
Please, please review carefully the NGS report. An opportunity not to be missed PYNNACLE trial.”
“Combined Tissue and combined tissue DNA NGS in solid tumours
Combined NGS detects more targetable alterations.
Combined Tissue DNA is quick and can change practice even more than tissue.”
ProvIDHe: phIIIb – Ivosidenib – mIDH1 (iCCA). Awaited safety/activity – heavily pretreated (>ClarIDHy) SOC NGS for IDH (=ClaIDHy (central)). ProvIDHE – 45 Spanish patients could access Ivosidenib.
Funding?”
“MO132 in PDAC at The European Society for Medical Oncology (ESMO) ESMOAsia24
Angela Lamarca, MD, PhD, MSc, is a Consultant in Medical Oncology at Jiménez Díaz Foundation University Hospital and The Christie NHS Foundation Trust. She also serves as an Honorary Consultant in Medical Oncology and Honorary Senior Lecturer at The University of Manchester. Dr. Lamarca specializes in gastrointestinal malignancies, particularly hepato-pancreato-biliary (HPB) cancers and neuroendocrine tumors (NETs).
More posts featuring Angela Lamarca.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023